inflammatory disease

Pandion Therapeutics, a biotechnology company, has raised $58 million at the completion of its Series A financing round, which will be used to advance its initial drug programmes for autoimmune and inflammatory diseases Read more


GSK and the Medical Research Council (MRC) are collaborating on an open innovation research initiative that aims to improve scientists’ understanding of inflammatory diseases that present a serious burden to patients. Read more


New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates. Read more